All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
EMA validates marketing authorization application for lisocabtagene maraleucel for the treatment of adults with B-cell non-Hodgkin lymphoma
Bookmark this article
On July 17, 2020, the European Medicines Agency (EMA) validated the marketing authorization application for lisocabtagene maraleucel (liso-cel), for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), and follicular lymphoma Grade 3B (FL3B) after at least two prior therapies.
Liso-cel is an investigational chimeric antigen receptor (CAR) T-cell therapy targeting CD19. The application was based on the results from
- the phase I TRANSCEND-NHL-001 (NCT02631044) study evaluating safety, antitumor activity, and pharmacokinetics of liso-cel in patients with R/R B-cell non-Hodgkin lymphoma, including DLBCL, high-grade lymphoma, PMBCL and FL3B
- the phase II TRANSCEND WORLD 001 study evaluating efficacy and safety of liso-cel in patients with aggressive B-cell non-Hodgkin lymphoma
With the validation of the application, the EMA can now start the centralized review process.
- BusinessWire. European Medicines Agency validates Bristol Myers Squibb’s application for CAR T cell therapy lisocabtagene maraleucel (liso-cel). https://www.businesswire.com/news/home/20200717005025/en/. Published Jul 17, 2020. Accessed Jul 21, 2020.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youNewsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox